HRP20191600T1 - Modulatori faktora b komplementa - Google Patents

Modulatori faktora b komplementa Download PDF

Info

Publication number
HRP20191600T1
HRP20191600T1 HRP20191600T HRP20191600T1 HR P20191600 T1 HRP20191600 T1 HR P20191600T1 HR P20191600 T HRP20191600 T HR P20191600T HR P20191600 T1 HRP20191600 T1 HR P20191600T1
Authority
HR
Croatia
Prior art keywords
segment
wing
compound
linked nucleosides
modified oligonucleotide
Prior art date
Application number
Other languages
English (en)
Inventor
Tamar R Grossman
Michael L Mccaleb
Andrew T Watt
Susan M Freier
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of HRP20191600T1 publication Critical patent/HRP20191600T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21047—Alternative-complement-pathway C3/C5 convertase (3.4.21.47), i.e. properdin factor B
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Claims (12)

1. Spoj koji obuhvaća modificiran oligonukleotid koji se sastoji od 20 vezanih nukleozida koji imaju nukleobaznu sekvencu koja obuhvaća sekvencu koja je navedena u SEQ ID NO: 440, 198, 228, 237, 444, 448, 450, 453, ili 455, pri čemu modificiran oligonukleotid obuhvaća: segment razmaka koji se sastoji od deset vezanih deoksinukleozida; 5’ segment „krila“ koji se sastoji od pet vezanih nukleozida; i 3’ segment „krila“ koji se sastoji od pet vezanih nukleozida; pri čemu se segment razmaka nalazi između 5’ segmenta „krila“ i 3’ segmenta „krila“, pri čemu svaki nukleozid iz svakog segmenta „krila“ obuhvaća 2’-O-metoksietil šećer; pri čemu svaka internukleozidna veza je fosforotioatna veza i pri čemu svaki citozin je 5-metilcitozin.
2. Spoj prema zahtjevu 1, pri čemu se modificiran oligonukleotid sastoji od 20 vezanih nukleozida koji imaju nukleobaznu sekvencu koja se sastoji od sekvence koja je navedena u SEQ ID NO: 440, pri čemu modificiran oligonukleotid obuhvaća: segment razmaka koji se sastoji od deset vezanih deoksinukleozida; 5’ segment „krila“ koji se sastoji od pet vezanih nukleozida; i 3’ segment „krila“ koji se sastoji od pet vezanih nukleozida; pri čemu se segment razmaka nalazi između 5’ segmenta „krila“ i 3’ segmenta „krila“, pri čemu svaki nukleozid iz svakog segmenta „krila“ obuhvaća 2’-O-metoksietil šećer; pri čemu svaka internukleozidna veza je fosforotioatna veza i pri čemu svaki citozin je 5-metilcitozin.
3. Spoj koji ima formulu: ili njegova farmaceutski prihvatljiva sol.
4. Spoj koji obuhvaća modificiran oligonukleotid koji se sastoji od 16 vezanih nukleozida koji imaju nukleobaznu sekvencu koja se sastoji od sekvence koja je navedena u SEQ ID NO: 598, pri čemu modificiran oligonukleotid obuhvaća: segment razmaka koji se sastoji od deset vezanih dezoksinukleozida; 5’ segment „krila“ koji se sastoji od tri vezana nukleozida; i 3’ segment „krila“ koji se sastoji od tri vezana nukleozida; pri čemu se segment razmaka nalazi između 5’ segmenta „krila“ i 3’ segmenta„krila“; pri čemu 5’ segment „krila“ obuhvaća 2’-O-metoksietil šećer, 2’-O-metoksietil šećer, i cEt šećer u 5’ do 3’ smjeru; pri čemu 3’ segment „krila“ obuhvaća cEt šećer, cEt šećer, i 2’-O-metoksietil šećer u 5’ do 3’ smjeru; pri čemu svaka internukleozidna veza je fosforotioatna veza; i pri čemu svaki citozin je 5-metilcitozin.
5. Spoj koji obuhvaća modificiran oligonukleotid koji se sastoji od 16 vezanih nukleozida koji imaju nukleobaznu sekvencu koja obuhvaća sekvencu koja je navedena u SEQ ID NO: 549, pri čemu modificiran oligonukleotid obuhvaća: segment razmaka koji se sastoji od deset vezanih deoksinukleozida; 5’ segment „krila“ koji se sastoji od tri vezana nukleozida; i 3’ segment „krila“ koji se sastoji od tri vezana nukleozida; pri čemu se segment razmaka nalazi između 5’ segmenta „krila“ i 3’ segmenta„krila“; pri čemu svaki nukleozid iz svakog segmenta „krila“ obuhvaća cEt šećer; pri čemu svaka internukleozidna veza je fosforotioatna veza; i pri čemu svaki citozin je 5-metilcitozin.
6. Spoj prema bilo kojem od zahtjeva 1 do 5, pri čemu se spoj sastoji od modificiranog oligonukleotida.
7. Spoj prema bilo kojem od zahtjeva 1 do 6, pri čemu modificiran oligonukleotid dalje obuhvaća konjugiranu grupu.
8. Sastav koji obuhvaća spoj prema bilo kojem od zahtjeva 1 do 7 i farmaceutski prihvatljiv nosač.
9. Spoj prema bilo kojem od zahtjeva 1 do 7, ili kompozicija prema zahtjevu 8, za upotrebu u liječenju, prevenciji, ili ublažavanju bolesti koja je povezana s disregulacijom alternativnog puta komplementa.
10. Spoj ili sastav za upotrebu prema zahtjevu 9, pri čemu je alternativni put komplementa aktiviran više od normalnog.
11. Spoj ili sastav za upotrebu prema zahtjevu 9, pri čemu je bolest makularna degeneracija, starosna makularna degeneracija (AMD), vlažna AMD, suha AMD, ili geografska atrofija.
12. Spoj ili sastav za upotrebu prema zahtjevu 9, pri čemu je bolest bolest bubrega, lupus nefritis, sistemski eritemski lupus (SLE), bolest gustih depozita (DDD), C3 glomerulonefritis (C3GN), CFHR5 nefropatija, ili atipični hemolitički uremijski sindrom (aHUS).
HRP20191600 2013-09-13 2019-09-04 Modulatori faktora b komplementa HRP20191600T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361877624P 2013-09-13 2013-09-13
PCT/US2014/055458 WO2015038939A2 (en) 2013-09-13 2014-09-12 Modulators of complement factor b
EP14844168.6A EP3043827B1 (en) 2013-09-13 2014-09-12 Modulators of complement factor b

Publications (1)

Publication Number Publication Date
HRP20191600T1 true HRP20191600T1 (hr) 2019-11-29

Family

ID=52666522

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191600 HRP20191600T1 (hr) 2013-09-13 2019-09-04 Modulatori faktora b komplementa

Country Status (33)

Country Link
US (4) US20160222389A1 (hr)
EP (2) EP3043827B1 (hr)
JP (3) JP6666250B2 (hr)
KR (1) KR102381790B1 (hr)
CN (2) CN112359042A (hr)
AU (2) AU2014318580B2 (hr)
BR (1) BR112016004671B1 (hr)
CA (1) CA2921842A1 (hr)
CL (2) CL2016000606A1 (hr)
CR (1) CR20160170A (hr)
DK (1) DK3043827T3 (hr)
DO (1) DOP2016000063A (hr)
EA (1) EA035433B1 (hr)
ES (1) ES2745758T3 (hr)
HK (1) HK1225638A1 (hr)
HR (1) HRP20191600T1 (hr)
HU (1) HUE045109T2 (hr)
IL (1) IL244095A0 (hr)
LT (1) LT3043827T (hr)
MA (1) MA38959A1 (hr)
MX (2) MX371518B (hr)
MY (1) MY181251A (hr)
PE (2) PE20190354A1 (hr)
PH (1) PH12016500443A1 (hr)
PL (1) PL3043827T3 (hr)
PT (1) PT3043827T (hr)
RS (1) RS59252B1 (hr)
RU (1) RU2662967C2 (hr)
SG (2) SG10201806787VA (hr)
SI (1) SI3043827T1 (hr)
UA (1) UA119046C2 (hr)
WO (1) WO2015038939A2 (hr)
ZA (1) ZA201601236B (hr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2092065T4 (da) 2006-10-18 2019-10-21 Ionis Pharmaceuticals Inc Antisense-forbindelser
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
BR112016004671B1 (pt) 2013-09-13 2020-12-29 Ionis Pharmaceuticals, Inc. compostos moduladores do fator b do complemento, composição compreendendo os referidos compostos e usos dos compostos ou da composição
BR112016013148B1 (pt) 2013-12-12 2024-02-27 Alnylam Pharmaceuticals, Inc ÁCIDO RIBONUCLEICO DE FITA DUPLA (dsRNA) PARA INIBIÇÃO DA EXPRESSÃO DO FATOR B DO COMPLEMENTO (CFB) EM UMA CÉLULA, COMPOSIÇÃO FARMACÊUTICA PARA INIBIÇÃO DA EXPRESSÃO DE UM GENE DO FATOR B DO COMPLEMENTO, SEU USO, E MÉTODO IN VITRO DE INIBIÇÃO DA EXPRESSÃO DO FATOR B DO COMPLEMENTO (CFB) EM UMA CÉLULA
LT3137596T (lt) * 2014-05-01 2019-09-10 Ionis Pharmaceuticals, Inc. Kompozicijos ir būdai, skirti komplemento b faktoriaus ekspresijos moduliavimui
TW201730341A (zh) * 2016-02-05 2017-09-01 Kyowa Hakko Kirin Co Ltd 抑制補體b因子之表現之反義寡核苷酸
ES2902006T3 (es) 2016-06-27 2022-03-24 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos médicos
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
WO2018117253A1 (ja) * 2016-12-23 2018-06-28 協和発酵キリン株式会社 補体ｂ因子の発現を抑制する核酸
WO2019027015A1 (ja) * 2017-08-02 2019-02-07 協和発酵キリン株式会社 核酸複合体
CA3078971A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
KR20230017789A (ko) * 2020-04-30 2023-02-06 알닐람 파마슈티칼스 인코포레이티드 보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
CN114057758A (zh) 2020-08-07 2022-02-18 上海美悦生物科技发展有限公司 补体因子b抑制剂及其药物组合物、制备方法和用途
CN114057692B (zh) 2020-08-07 2023-07-21 上海美悦生物科技发展有限公司 一种杂环类化合物、其制备方法及用途
WO2023018523A2 (en) * 2021-07-17 2023-02-16 Sirnaomics, Inc. Products and compositions
AU2022336157A1 (en) 2021-09-02 2024-03-14 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
WO2023076451A1 (en) * 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
WO2023129496A2 (en) * 2021-12-27 2023-07-06 Apellis Pharmaceuticals, Inc. Rnas for complement inhibition

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
ATE190981T1 (de) 1989-10-24 2000-04-15 Isis Pharmaceuticals Inc 2'-modifizierte nukleotide
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ATE167523T1 (de) 1990-05-11 1998-07-15 Microprobe Corp Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden
ES2103918T3 (es) 1991-10-17 1997-10-01 Ciba Geigy Ag Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
RU95114435A (ru) 1992-12-14 1997-05-20 Ханивелл Инк. (Us) Система с бесщеточным двигателем постоянного тока
EP0691968B1 (en) 1993-03-30 1997-07-16 Sanofi Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US7875733B2 (en) 2003-09-18 2011-01-25 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
WO2000021559A2 (en) * 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
CA2370628A1 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
JP2003519231A (ja) 1999-12-30 2003-06-17 カー・ユ・ルーベン・リサーチ・アンド・ディベロップメント シクロヘキセン核酸
WO2003004602A2 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
JP4634799B2 (ja) * 2002-09-13 2011-02-16 ライフ テクノロジーズ コーポレーション 耐熱性逆転写酵素およびその使用法
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
CA2504929C (en) 2002-11-05 2014-07-22 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
WO2004103288A2 (en) * 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
WO2005121372A2 (en) 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
EP1799859B1 (en) * 2004-09-17 2014-07-02 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
WO2006047842A2 (en) 2004-11-08 2006-05-11 K.U. Leuven Research And Development Modified nucleosides for rna interference
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
CN102766630B (zh) 2006-01-27 2014-05-07 Isis制药公司 6-修饰的双环核酸类似物
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
US8809514B2 (en) * 2006-09-22 2014-08-19 Ge Healthcare Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference
CN101589143A (zh) * 2006-11-27 2009-11-25 Isis药物公司 用于治疗高胆固醇血症的方法
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
CA2678774A1 (en) * 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
AU2008260277C1 (en) 2007-05-30 2014-04-17 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
ES2376507T5 (es) 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos
US8703730B2 (en) * 2008-07-10 2014-04-22 Regenesance B.V. Complement antagonists and uses thereof
WO2010036696A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acid analogs
US8993738B2 (en) 2010-04-28 2015-03-31 Isis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
EP3489360A3 (en) * 2010-07-19 2019-08-28 Ionis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
CA2832972C (en) * 2011-04-13 2019-04-30 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
BR112016004671B1 (pt) 2013-09-13 2020-12-29 Ionis Pharmaceuticals, Inc. compostos moduladores do fator b do complemento, composição compreendendo os referidos compostos e usos dos compostos ou da composição
LT3137596T (lt) * 2014-05-01 2019-09-10 Ionis Pharmaceuticals, Inc. Kompozicijos ir būdai, skirti komplemento b faktoriaus ekspresijos moduliavimui

Also Published As

Publication number Publication date
MX371518B (es) 2020-01-31
AU2014318580B2 (en) 2019-12-12
EA201690582A1 (ru) 2016-07-29
WO2015038939A2 (en) 2015-03-19
PT3043827T (pt) 2019-09-26
JP7297112B2 (ja) 2023-06-23
US20160222389A1 (en) 2016-08-04
HUE045109T2 (hu) 2019-12-30
US20220243209A1 (en) 2022-08-04
US11926830B2 (en) 2024-03-12
CN105744959A (zh) 2016-07-06
JP2016533765A (ja) 2016-11-04
CA2921842A1 (en) 2015-03-19
WO2015038939A3 (en) 2015-07-02
SI3043827T1 (sl) 2019-08-30
JP2022058784A (ja) 2022-04-12
BR112016004671B1 (pt) 2020-12-29
HK1225638A1 (zh) 2017-09-15
EA035433B1 (ru) 2020-06-15
EP3043827A4 (en) 2017-05-24
CN112359042A (zh) 2021-02-12
RU2016113763A (ru) 2017-10-16
MX2016003263A (es) 2016-12-08
PH12016500443A1 (en) 2016-05-16
DOP2016000063A (es) 2016-06-01
IL244095A0 (en) 2016-04-21
SG11201601445XA (en) 2016-03-30
MX2020001258A (es) 2020-03-20
AU2014318580A1 (en) 2016-03-03
EP3043827A2 (en) 2016-07-20
KR102381790B1 (ko) 2022-03-31
KR20160054595A (ko) 2016-05-16
PL3043827T3 (pl) 2020-03-31
CL2018002334A1 (es) 2018-12-14
JP7158363B2 (ja) 2022-10-21
CL2016000606A1 (es) 2017-02-17
JP6666250B2 (ja) 2020-03-13
PE20190354A1 (es) 2019-03-07
ES2745758T3 (es) 2020-03-03
AU2020201763A1 (en) 2020-04-02
EP3603677A1 (en) 2020-02-05
ZA201601236B (en) 2017-05-31
SG10201806787VA (en) 2018-09-27
RU2662967C2 (ru) 2018-07-31
CR20160170A (es) 2016-07-15
MA38959A1 (fr) 2017-08-31
LT3043827T (lt) 2019-08-12
EP3043827B1 (en) 2019-07-03
MY181251A (en) 2020-12-21
PE20160500A1 (es) 2016-05-21
CN105744959B (zh) 2020-12-01
DK3043827T3 (da) 2019-08-26
UA119046C2 (uk) 2019-04-25
US20200149047A1 (en) 2020-05-14
US20190048351A1 (en) 2019-02-14
RS59252B1 (sr) 2019-10-31
JP2020036600A (ja) 2020-03-12

Similar Documents

Publication Publication Date Title
HRP20191600T1 (hr) Modulatori faktora b komplementa
HRP20191664T1 (hr) Sastavi i postupci za moduliranje ekspresije komplementa faktora b
HRP20211397T1 (hr) Pripravci za modulaciju ekspresije ataksina 2
HRP20200843T1 (hr) Sastavi za moduliranje ekspresije c9orf72
HRP20201426T1 (hr) Postupci i pripravci za moduliranje ekspresije apolipoproteina (a)
HRP20211365T1 (hr) Pripravci i postupci za modulaciju ekspresije proteinske kinaze miotonične distrofije (dmpk)
HRP20200042T1 (hr) Suprotne nukleinske kiseline za uporabu u liječenju duchennove mišićne distrofije
NO2019001I1 (no) Forbindelse omfattende et modifisert oligonukleotid som har en nukleobasesekvens bestående av 20 koblede nukleosider ifølge EP B1 2563920 krav 1 (SEQ ID NO: 80), hvor det modifiserte oligonukleotidet omfatter: et avstandssegment bestående av ti koblede deoksynukleosider; et 5'-vingesegment bestående av fem koblede nukleosider; og et 3'-vingesegment bestående av fem koblede nukleosider; hvor avstandssegmentet er plassert mellom 5'-vingesegmentet og 3'-vingesegmentet, hvor hvert nukleosid av hvert vingesegment omfatter et 2'-0-metoksyetylsukker; hvor hver cytosin av det modifiserte oligonukleotid er en 5-metylcytosin, og hvor hver internukleosid-binding av det modifiserte oligonukleotid er en fosfortioatbinding; og spesielt inotersen; og dets derivater, så som dets salter, inkludert natriumsalter.
HRP20211051T1 (hr) Pripravci namijenjeni moduliranju eksprimiranja tau
JP2013226147A5 (hr)
HRP20190303T1 (hr) Liječenje raka
JP2020058368A5 (hr)
AU2024201770A1 (en) Complement component iRNA compositions and methods of use thereof
HRP20201078T1 (hr) Pripravci namijenjeni moduliranju eksprimiranja sod-1
HRP20201023T1 (hr) Dioksilan analozi uridina za liječenje raka
CL2014001641A1 (es) Compuestos derivados de nucleosidos sustituidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y uso para mejorar o tratar una infeccion viral.
HRP20201125T1 (hr) Antisens nukleinska kiselina
HRP20200521T1 (hr) Kombinacijske terapije za liječenje kemorezistentnih rakova
RU2016116849A (ru) Композиции для модуляции экспрессии c90rf72
FR2926553B1 (fr) Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
BR112015022522A2 (pt) engenharia de genomas de planta usando sistemas crispr/cas
JP2016526529A5 (hr)
SA517382236B1 (ar) نيوكليدات بيورين مستبدلة بـ 2- n6 معدل مستبدل بــــ بيتا-d-2´-ديوكسي-2´-ألفا-فلورو-2 ´-بيتا-c لمعالجة hcv
JP2017510271A5 (hr)
JP2014530004A5 (hr)